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Abstract 
 
There have been reports of strong correlations between poor prognosis in 
various cancers and concomitant expression of urokinase-type plasminogen activator 
(uPA) and its surface receptor (uPAR). We and others have previously shown that the 
uPA system plays a significant role in a subset of head and neck squamous cell 
carcinoma. In the present study, we found that uPAR is required for invasion and 
metastasis of highly malignant oral cancer cells (OSC-19). Treating OSC-19 cells with 
antisense oligonucleotides (AS) targeting uPAR resulted in a dramatic decrease of uPAR 
mRNA expression. Furthermore, pretreatment with AS or siRNA targeting uPAR 
inhibited progression of OSC-19 cells in experimental models. These results suggest 
that overexpression of uPAR increases the invasiveness and metastasis of OSC-19 cells, 
and that uPAR is a promising therapeutic target for regulation of progression of oral 
cancer. 
 
Keywords: Antisense oligonucleotide; small interfering RNA; Urokinase-type 
plasminogen activator receptor; Oral squamous cell carcinoma 
Introduction 
 
Several proteolytic enzyme systems, involving plasminogen activators (PAs), 
matrix metalloproteinases (MMPs) and other enzymes, are thought to be intimately 
involved in invasion and metastasis of tumor cells [1]. Urokinase-type PA (uPA), which 
plays an essential role in conversion of PA to active plasmin and proteolysis of 
extracellular matrix (ECM), has been implicated in cancer cell invasion and metastasis 
[2, 3]. In particular, the activity of receptor (uPAR)-bound uPA is an important factor in 
the degradation ECM [4, 5]. 
In a previous study, we found that cells overexpressing both uPAR and uPA 
mRNA were more invasive and aggressive in an in vivo experimental metastasis model 
[6]. In immunohistochemical studies, the uPA system has been found to be significantly 
associated with mode of invasion [7] and secondary regional lymph node metastasis of 
squamous cell carcinoma (SCC) in the oral cavity [8]. The majority of studies of the 
uPA system in oral SCC have shown that patterns of expression of the uPA system 
correlate with metastatic ability of cancer cells or clinicopathological observations. In 
the present study, we examined overexpression of uPAR mRNA in OSC-19 cells 
derived from human oral SCC, and examined the function of uPAR using antisense 
oligodeoxynucleotides (AS-ODNs) and small interfering RNA (siRNA). We found that 
uPAR is required for invasion and metastasis of OSC-19 cells in the present in vivo 
models. Additionally, transfection of cells with uPAR siRNA inhibited degradation of 
fibronectin. These findings provide the first direct, conclusive evidence that reduction of 




Materials and Methods 
 
Cell line and antibodies 
 
OSC-19 cells were previously established from a metastatic tumor in a 
cervical lymph node of a patient with grade-4C (cordlike type) SCC of tongue. In the 
present study, OSC-19 cells derived from human oral SCC were maintained in Eagle’s 
minimum essential medium (EMEM; Nissui Seiyaku, Tokyo, Japan) supplemented with 
10% fetal bovine serum (Filtron, Brooklyn, Australia), in an atmosphere of 5% CO2 and 
95% air at 37˚C. The anti-actin monoclonal antibody was purchased from Molecular 
Probes, Inc. (Eugene, OR, USA). Fluorescein (FITC)- and Cy5-linked secondary 




An 18-mer ODN phosphodiester was used to inhibit uPAR gene expression 
[9]. The ODNs were protected against exonuclease cleavage by a double substitution at 
the 3’-end and 5’-end with phosphorothioate residues, and were purified by 
high-performance liquid chromatography (JBioS, Asagiri, JAPAN). The AS-uPAR 
corresponded to nucleotides 44 to 61 of the human uPAR gene cDNA sequence [10]. 
The controls consisted of sense (S)- and nonsense (NS)-ODNs (same base composition 
as AS-uPAR, but in random order) for uPAR. The sequence of the NS-uPAR was 
5’-CCTGGGTCAGCGCGCTAG-3’. Cells were suspended in EMEM at a density of 
106 cells/ml, and were incubated with medium alone or with 40 µM ODNs for 60 min at 
37°C. Cell viability exceeding 95% was confirmed by trypan blue exclusion before 
ODN-treated cells were used in experiments. 
 
Reverse transcription (RT)-PCR 
 
RT-PCR analysis was performed using the modifications of Conboy et al. [11]. 
Briefly, total RNA was extracted from cancer cells using a 
guanidinium-isothiocyanate-phenol-chloroform-based method (ISOGENE, Nippon 
Gene, Tokyo, Japan). The prepared RNA was mixed with the oligo-dT primer, incubated 
for 15 min at 68°C, and then quickly chilled on ice for 5 min. The RNA samples were 
reverse-transcribed into first-strand cDNA at 42°C for 60 min in RT solution [11]. The 
cDNA samples were amplified by adding a PCR mixture [11]. The amplification was 
performed as described previously by Noguchi-Takino et al. [12]. Primers for the uPAR 
and ß-actin genes were used as described by Noguchi-Takino et al. [12]. The lengths for 
the amplified fragments of the uPAR and ß-actin genes were 455 and 592 bp, 
respectively. 
For quantitation, PCR product values of the uPAR gene, falling within the 
linearity range, were normalized to that of the ß-actin gene, which was used as an 
internal standard. 
 
Orthotopic implantation model 
 
The mode of cancer invasion in a tumor-host relationship closely correlates 
with clinical course. In a study of SCC of the oral cavity, Yamamoto et al. [7] graded 
mode of invasion, and showed that grade 4C and 4D (diffuse invasion) had poor 
prognosis. To evaluate the effect of AS-uPAR on mode of invasion, we injected cells 
pretreated with ODNs into the submucosa of the oral floor. The present xenograft model 
is described in detail elsewhere by Kawashiri et al. [13]. Briefly, 6-week-old female 
BALB/c nude mice (Charles River Japan, Yokohama, Japan) were used. Tumor cells (2 
x 105 cells/mouse) were injected into the submucosa of the oral floor using a 
microsyringe with a 27-gauge needle. After 7 days, the tumors were excised and 
examined histopathologically. 
In this orthotopic implantation model, the OSC-19 cells deeply invade, 
forming small cordlike cancer nests, which indicate grade 4C mode of invasion [13]. 
 
Chick embryo assay 
 
The metastatic ability of OSC-19 cell lines pretreated with ODNs was 
examined using the chick embryo assay. The assay for metastasized cells was performed 
as described previously by Endo et al. [14]. Briefly, fertilized chicken eggs were 
incubated in a forced-air incubator at 37˚C in a humidified atmosphere. Tumor cells 
(106 cells/egg) were injected into the choriallantoic membrane (CAM) vein of 
10-day-old chick embryos. The embryos were sacrificed 7 days after tumor cell 
inoculation. The embryonic liver and lung were then dissected, and DNA was extracted 
from them. A fragment of the human ß-globin gene in human tumor cells that 
metastasized into chick embryonic organs was specifically amplified by PCR. The 
amplified fragment was separated electrophoretically in a 1.5% agarose gel. The 
specific primers for the ß-globin gene were Huß-1 
(5’-AGAGCCATCTATTGCTTACA-3’) and Huß-8 





The 21-nucleotide-long siRNAs were chemically synthesized, desalted, 
deprotected and purified using polyacrylamide-gel electrophoresis. Two 
oligoribonucleotides (5'-GGUGAAGAAGGGCGUCCAATT-3' and 
5'-UUGGACGCCCUUCUUCACCTT-3') labeled with the fluorescent dye TAMRA at 
the 5' end were used to inhibit uPAR synthesis (Ambion, Austin, TX, USA). As a 
control, we used 2 nonsense siRNA oligoribonucleotides: 
5'-UUCUCCGAACGUGUCACGUTT-3' and 5'-ACGUGACACGUUCGGAGAATT-3' 
(Qiagen, Valencia, CA, USA). Cells were transfected with the oligoribonucleotides 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The transfection was 
performed overnight on subconfluent cells, with a final siRNA concentration of 40 nM. 
In each experiment, a series of cells was used for RT-PCR to evaluate inhibition of 
uPAR expression. 
 
In vitro fibronectin degradation/invasion assays 
 
We investigated the possibility that uPAR is involved in invasiveness of 
OSC-19 cells, using the fibronectin degradation/invasion assay with OSC-19 cells 
transfected with siRNA targeting uPAR. Cells transfected with the oligoribonucleotides 
were collected by trypsinization, and 105 cells were added to FITC-fibronectin-coated 
crosslinked gelatin films on an 18-mm round glass cover slip in a 12-well plate, as 
described elsewhere [15, 16]. This technique allows us to measure the fibronectin 
degradation and the invasiveness in terms of foci of invadopodial extensions and 
surface indentations in the crosslinked gelatin film. Invasive cells locally degrade the 
FITC-fibronectin-coated matrix, leaving a dark area easily detectable by 
immunofluorescence microscopy in the in vitro fibronectin degradation/invasion assay, 
as described in detail elsewhere [15, 16]. After the cells were allowed to grow on the 
films for the indicated periods of time, they were examined using an MRC-1024 
confocal laser-scanning microscope (Bio-Rad, UK). To quantify the degraded area of 
FITC-fibronectin, we used NIHimage to calculate the area of the black region (30 pixel 




All experiments were repeated 3 times, and similar results were obtained each 
time. The statistical significance of differences between groups was evaluated using a 





Effect of treatment with AS-uPAR on uPAR mRNA level 
 
The pretreatment of OSC-19 cells for 60 min with 40 µM AS-uPAR resulted 
in a dramatic decrease of uPAR mRNA levels (Figure 1). The cells treated with S- or 
NS-uPAR had the same uPAR/ß-actin ratio as the control cells. The cells treated with 
AS-uPAR had a uPAR/ß-actin ratio that was 57% less than that of the control cells. 
 
Effects of ODNs for uPAR on mode of invasion 
 
In control groups that were untreated or were pretreated with S- or NS-uPAR, 
all oral floor tumors were Grade 4C. In contrast, in the group pretreated with AS-uPAR, 
diffuse invasion was inhibited and the tumors were Grade 3; i.e., they consisted of 
groups of cells without a distinct borderline (Figure 2). In the group treated with 
AS-uPAR intratumorally on day 3 after the injection of untreated tumor cells, the 
tumors were the same as in the control groups. 
 
Effects of pretreatment with ODNs for uPAR on experimental metastases 
 
In control groups, metastasized cells were observed in the chick liver (Figure 
3). The pretreatment of OSC-19 cells for 60 min with 40 µM AS-uPAR resulted in a 
dramatic decrease of liver metastases (Figure 4). Liver metastases were not affected by 
pretreatment with S- or NS-uPAR. In cells treated with AS-uPAR, metastasis was 
inhibited by 86%. Additionally, AS-uPAR exhibited a significant antitumor effect 
against lung metastases (data not shown). 
 
Effect of transfection with siRNA targeting uPAR on in vitro fibronectin 
degradation/invasion assay 
 
The transfected cells were detectable under immunofluorescence microscopy 
(Figure 5A), and were morphologically similar to control cells (Figure 5B). Transfection 
of cells with uPAR siRNA resulted in a dramatic decrease of fibronectin degradation 
(Figure 6A). Fibronectin degradation was not affected by transfection of nonsense 






In the present study, we showed that AS-uPAR inhibits overexpression of 
uPAR in highly malignant oral cancer cells (OSC-19). We also demonstrated that uPAR 
plays an important role in the progression of oral cancer cells. We observed an 
especially strong relationship between the uPA system and initial invasion of oral cancer 
cells. 
A specific cell surface receptor for the ligand uPA catalyzes the formation of 
plasmin from PA, thus generating the proteolytic cascade that contributes to the 
breakdown of ECM, which is a key step in cancer metastasis [2, 3]. Recent studies by 
Aguirre-Ghiso et al. have demonstrated signaling via uPAR in cancer cells in vivo [17, 
18]. They showed that a large reduction in the uPAR level induced a protracted state of 
tumor dormancy, but did not affect in vitro growth [17]. Further analysis revealed that 
the overexpressed uPA/uPAR complex interacted strongly with α5ß1 integrin, resulting 
in powerful and persistent activation of the Mek-ERK pathway upon binding to 
fibronectin [17, 18]. When uPAR was downregulated or the uPAR-α5ß1 interaction was 
disrupted, the ERK pathway became deactivated, the cell arrested in the G0/G1 phase of 
the cell cycle in vivo, and tumor dormancy was triggered in vivo [17, 18]. In the present 
study, AS-uPAR inhibited invasion and metastasis in vivo but did not inhibit in vitro 
growth. This suggests that the same mechanism is at work in the present in vivo 
experimental models and the studies by Aguirre-Ghiso et al. α5ß1 integrin is the 
fibronectin receptor, and the uPAR siRNA decreased the fibronectin degradation. 
Recent reports suggest that regulation of uPAR expression is a viable method 
of controlling cancer progression in vivo. Crowley et al. [19] reported that a mutant uPA 
molecule that binds to uPAR but lacks enzyme activity inhibited metastasis of PC3 
prostate cancer cells in an immunodeficient mouse model. Similarly, blocking uPAR 
with the epidermal growth factor-like domain of murine uPA suppresses 
neovascularization and growth of B16 melanomas [20]. Recently, researchers have 
developed various agents that target uPAR, including AS-ODN, siRNA, protein and 
peptide-based drugs [21-23]. These reports suggest that uPAR is a promising therapeutic 
target for regulation of cancer progression. The present results indicate that our strategy 
for targeting uPAR is an effective method of inhibiting progression of oral SCC. 
However, in previous in vivo studies, cancer progression was only weakly inhibited by 
antisense uPAR mRNA. This discrepancy may be due to the activity of other 
proteinases (including MMPs) that play central roles in the process of cancer invasion 
and metastasis. OSC-19 cells express high levels of some MMPs (data not shown). 
Therefore, in addition to reduction of uPAR expression, other strategies may be needed 
to obtain more effective and reliable inhibition of cancer progression. 
The uPAR promoter region is located in a 188-bp region between bases -141 and +47, 
relative to the transcription start site [3]. Binding of transcription factors (Sp1, AP-2, 
NF-κB and 2 molecules of AP-1) to the uPAR promoter region activates basal 
transcription of the gene. NF-κB also induces expression of proteinases (uPA, MMP-1, 
and -9) [24-26]. Thus, drugs that inhibit activity of NF-κB may inhibit cancer invasion 
and metastasis. We have previously shown that parthenolide, an active ingredient of 
herbal remedies such as feverfew (tanacetum parthenium), decreases NF-κB 
DNA-binding activity and expression of target genes of NF-κB [27, 28]. In studies of 
the uPAR promoter, Shiratsuchi et al. [29] and Hapke et al. [30] investigated reduction 
of uPAR expression via methods involving AP-1 and a PEA3/ets transcriptional element, 
respectively. Their results suggest that methods targeting transcriptional elements could 
be useful complementary therapies together with reduction of uPAR expression. 
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Figure Captions 
Fig. 1. Gene expression of uPAR in OSC-19 cells treated with ODNs. Cells suspended 
in EMEM at a density of 106 cells/ml were incubated with 40 μM ODNs for 60 min at 
37°C. An RNA sample from each group was analyzed by RT-PCR. The lengths of the 
uPAR and ß-actin fragments were 455 and 592 bp, respectively. 
Fig. 2. Histologic photomicrographs of the oral floor tumor. (A) This tumor exhibited 
the grade-4C mode of invasion (control group). (B) This tumor exhibited the grade-3 
mode of invasion, suggesting reduced invasiveness as a result of antisense therapy 
(AS-uPAR group). H & E stain. Bar = 0.1 mm. 
Fig. 3. Histologic photomicrographs of embryonic liver on day 7 after OSC-19 cell 
inoculation (control group). H & E stain. Bar = 0.4 mm. 
Fig. 4. Detection of metastasized OSC-19 cells in chick embryo liver. Tumor cells (106 
cells/egg) pretreated with ODNs were injected into the CAM vein of 10-day-old chick 
embryos. After 7 days, 6 embryos from each group were sacrificed and the liver DNA 
was extracted. The sample DNA was analyzed by PCR using a primer pair specific to 
the human ß-globin gene. 
Fig. 5. Immunofluorescence photomicrographs of control cells and the cells transfected 
with uPAR siRNA. (A) The transfected cells were red colored (siRNA labeled with the 
fluorescent dye TAMRA), but control cells were not. (B) The transfected cells were 
morphologically similar to control cells (blue: actin staining labeled with Cy-5). Bar = 
10 μm. 
Fig. 6. The uPAR siRNA inhibited fibronectin degradation. (A) Transfection of cells 
with uPAR siRNA resulted in a dramatic decrease of fibronectin degradation (black 
region). (B) Fibronectin degradation was not affected by transfection with nonsense 
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